Editorials Oct 19, 2013
It still isn't clear who manipulated clinical research data in favor of Novartis Pharma's blood-pressure drug Diovan, casting a cloud on the credibility of Japan's medical universities.
In an effort to speak with an authoritative voice on issues we deem important, The Japan Times Editorial Board produces a single editorial each week that offers a fresh and informed perspective. The weekly editorial appears online every Friday and is published in print in The Japan Times Weekend edition.
It still isn't clear who manipulated clinical research data in favor of Novartis Pharma's blood-pressure drug Diovan, casting a cloud on the credibility of Japan's medical universities.
The Oct. 11 fire that killed 10 people at a Fukuoka orthopedic clinic is a warning to the central and local governments of the consequences of letting fire-prevention equipment go unchecked.